Administration of G‐CSF did not increase the risk of AML relapse following BMT, PBSCT, or CBT, regardless of cytogenetic risk or disease status at HCT, except for a significant effect of G‐CSF administration on relapse based on disease status following PBSCT (p for interaction = .049) (Figure S3). Here, CSF3 is linked to acute myeloid leukemia.